Drug Trial Radar · NCT07477639
Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis
Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
39
Planned (sponsor's estimate)
Start
Mar 1, 2026
Primary completion
Aug 2028
Study completion Jan 2029
Sponsor
- Lead sponsor
- Tr1X, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 17, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to treat male and female participants with two types of Multiple Sclerosis (MS) called primary progressive or secondary progressive MS. The main questions the trial aims to answer are the following: * Is TRX319 safe when administered to patients with progressive forms of MS? * At what dose does TRX319 work the best to treat participants with primary and or secondary progressive MS? * Is pre-conditioning (with Bendamustine) needed to allow TRX319 to better treat participants with primary and/or secondary progressive MS? Participants will be asked to be on study for up 1 year and may receive up to 3 total administrations of TRX319. While on study, participants will have blood tests and other assessments (MRI scans and lumbar punctures) done to understand the safety of TRX319 and how it may benefit their multiple sclerosis.
Conditions
- Primary Progressive Multiple Sclerosis
- Secondary Progressive Multiple Sclerosis (SPMS)
- Multiple Sclerosis
- Multiple Sclerosis (MS) Primary Progressive
- Multiple Sclerosis (MS) Secondary Progressive
Interventions
TRX319Biological
TRX319 is an investigational research cell therapy that may treat and provide long term relief to individuals suffering from Primary Progressive Multiple Sclerosis and/or Secondary Progressive Multiple Sclerosis.
BendamustineDrug
Administration of bendamustine prior to TRX319 infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- To assess the safety and tolerability of TRX319 infusion in subjects with Primary Progressive or Secondary Progressive Multiple Sclerosis.Time frame: From baseline until 12 months post TRX319 Infusion
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
UC San Diego
La Jolla, California · Recruiting
University of Kansas Medical Center
Kansas City, Kansas · Recruiting
Mayo Clinic
Rochester, Minnesota · Recruiting
Washington University, St. Louis
St Louis, Missouri · Recruiting
Mt. Sinai
New York, New York · Recruiting
Duke University
Durham, North Carolina · Recruiting
University of Cincinnati
Cincinnati, Ohio · Recruiting
Providence Swedish
Seattle, Washington · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.